We recently showed that TGFβ treatment in normal and thyroid cancer cell lines induces EMT through the activation of RUNX2 and its target CDH6.55, 56, 57 CDH6 silencing reverts the EMT phenotype and restrains migration and invasiveness in thyroid cancer cells. Here, RUNX2 is linked to thyroid gland carcinoma.